Triad Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Triad Therapeutics Inc. hopes to accelerate the drug discovery process through the use of its IOPE technology, which it claims significantly accelerates the discovery of nanomolar-affinity hits over those obtained with other currently available technologies. IOPE exploits NMR spectroscopy to map key structural elements among the members of individual classes of enzymes and then uses the data to design libraries of compounds biased to bind to targets of the class, in effect starting the medicinal chemistry process with a compound that is much closer to a development lead.